Verbatim response from ChatGPT
Short answer
- Many people see noticeable weight loss within the first 2–3 months on a GLP‑1 or related drug, and average losses in clinical trials after ~6–12 months are roughly:
- Semaglutide (Wegovy): about 10–15% of body weight on average at ~68 weeks.
- Tirzepatide (Zepbound/Mounjaro): generally larger average losses in trials — often 15–25% at ~72 weeks depending on dose.
- Real-world results vary a lot. Weight loss tends to be fastest early (first 3–6 months) and slows after that.
- Sustainability: most evidence shows continued medication is usually required to keep the weight off; stopping often leads to partial or full regain unless intensive lifestyle changes are maintained.
More detail
How fast you’ll lose it
- Typical pattern: a relatively rapid initial phase (weeks to a few months) as appetite drops and calorie intake falls, then a slower, steadier phase. Many patients lose several percent of body weight in the first 3 months and may reach double‑digit percentage loss by 6–12 months on an effective dose.
- Trial averages (helpful for setting expectations): semaglutide 2.4 mg (Wegovy) trials reported roughly 10–15% average loss at ~68 weeks; tirzepatide (studied as Mounjaro for diabetes and Zepbound for weight management) produced larger average losses in trials — frequently in the mid‑teens up toward ~20%+ at 72 weeks for higher doses. Individual results range from minimal loss to very large losses.
- Rate varies by starting weight, dose, adherence, diet/activity, side effects, and biology. Expect more rapid per‑week losses early on, then slowing — that’s normal.
Is it sustainable?
- GLP‑1s/tirzepatide change appetite and food intake, which helps a lot while you take them. Clinical and follow‑up data show that stopping the drug commonly leads to weight regain over months to years unless people keep up strong lifestyle changes or switch to another maintenance strategy.
- For many patients, long‑term treatment (years) is what’s needed to maintain the loss, similar to other chronic conditions that require ongoing medication.
- Combining medication with structured behavioral support (nutrition, exercise, habit change) improves the chance of sustained success and reduces regain when/if medication is stopped.
Safety and monitoring
- Common side effects: nausea, vomiting, diarrhea, constipation, and decreased appetite. These often lessen with gradual dose escalation.
- Less common but important: pancreatitis, gallbladder problems, and — in animal studies — thyroid C‑cell tumors; there are contraindications (personal or family history of medullary thyroid carcinoma or MEN2). Work with your clinician for baseline labs and periodic monitoring.
- Discuss interactions, pregnancy plans, and other medical conditions with your prescriber.
Which products and services to consider
- Medications:
- Wegovy (semaglutide) — FDA‑approved for chronic weight management; substantial trial data.
- Zepbound (tirzepatide) — FDA‑approved for weight management; trials show larger average losses than semaglutide at some doses.
- Ozempic (semaglutide) and Mounjaro (tirzepatide) — diabetes medicines using the same molecules; sometimes used (or considered off‑label) for weight in clinical practice.
- Support services to improve sustainability:
- See an ABOM‑certified obesity medicine specialist or your primary care doctor experienced with GLP‑1s.
- Work with a registered dietitian (RD) for individualized eating plans.
- Behavioral/maintenance programs: CDC Diabetes Prevention Program (DPP), commercial programs like WW or app‑based programs (Noom) can add structure and accountability.
- Consider a structured exercise plan and behavioral therapy to solidify habits.
Next steps
- If you’re thinking about starting a GLP‑1/tirzepatide: talk to your healthcare provider about risks, benefits, dosing schedule, expected timeline for your situation, cost/insurance coverage, and a plan for combining medication with lifestyle and follow‑up.
- If you want, tell me your current weight, height, any medical conditions and medications, and whether you have access/insurance coverage, and I can give a more personalized expectation and next‑step plan.